Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 71 out of 100. Risk factors

Topic: Risk, prevention and care in population studies

Plain-language summary

Dementia with Lewy bodies and Parkinson's disease dementia, jointly known as Lewy body dementia, are common neurodegenerative conditions. Patients with Lewy body dementia present with a wide range of cognitive, neuropsychiatric, sleep, motor, and autonomic symptoms. Presentation varies between patients and can vary over time within an individual. Treatments can address one symptom but worsen another, which makes disease management difficult. Symptoms are often managed in isolation and by different specialists, which makes high-quality care difficult to accomplish. Clinical trials and meta-analyses now provide an evidence base for the treatment of cognitive, neuropsychiatric, and motor symptoms in patients with Lewy body dementia. Furthermore, consensus opinion from experts supports the application of treatments for related conditions, such as Parkinson's disease, for the management of common symptoms (eg, autonomic dysfunction) in patients with Lewy body dementia. However, evidence gaps remain and future clinical trials need to focus on the treatment of symptoms specific to patients with Lewy body dementia.

What this study adds

Evidence grade: High

This is a pooled review. This review states that clinical trials and meta-analyses now provide an evidence base for treating cognitive, neuropsychiatric, and motor symptoms in Lewy body dementia, but that treatments can improve one symptom while worsening another and evidence gaps remain. It is about managing symptoms of Lewy body dementia, not curing or preventing Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Taylor, J. P., McKeith, I. G., Burn, D. J., Boeve, B. F., Weintraub, D., Bamford, C., et al. (2020). New evidence on the management of Lewy body dementia. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(19)30153-x

Vancouver

Taylor JP, McKeith IG, Burn DJ, Boeve BF, Weintraub D, Bamford C, et al. New evidence on the management of Lewy body dementia. The Lancet. Neurology. 2020. doi:10.1016/s1474-4422(19)30153-x. PMID: 31519472.

BibTeX

@article{taylor2020-31519472,
  author  = {Taylor, J. P. and McKeith, I. G. and Burn, D. J. and Boeve, B. F. and Weintraub, D. and Bamford, C. and Allan, L. M. and Thomas, A. J. and others},
  title   = {{New evidence on the management of Lewy body dementia}},
  journal = {The Lancet. Neurology},
  year    = {2020},
  doi     = {10.1016/s1474-4422(19)30153-x},
  pmid    = {31519472},
  url     = {https://doi.org/10.1016/s1474-4422(19)30153-x}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This review states that clinical trials and meta-analyses now provide an evidence base for treating cognitive, neuropsychiatric, and motor symptoms in Lewy body dementia, but that treatments can improve one symptom while worsening another and evidence gaps remain. It is about managing symptoms of Lewy body dementia, not curing or preventing Alzheimer's disease.

Study details

How this study scored 71/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 3 of 4; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 4 of 6; Cited by studies here 3 of 6; Still being cited 3 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 71 of 100.71 of 100 points earned29 not earned

Published in a leading specialty journal, and it is a meta-analysis pooling many studies. Scored zero for sample size, effect reported and studied in people because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (The Lancet. Neurology)
Journal's citation record 3 / 4 The Lancet Neurology: journal h-index 457 (OpenAlex, 2026-10-29)
Study design 12 / 12 A meta-analysis pooling many studies
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2020 — within 10 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 6 / 7 Cited 342 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 42.8 citations a year over 8 year(s) since 2020
Impact for its field and year 4 / 6 Cited 17.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 24 other studies in this library
Still being cited 3 / 4 Cited 161 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author John Tiernan O'Brien: h-index 140 (OpenAlex, whole career)
Institution's track record 2 / 3 University of Cambridge: institution h-index 1,973 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 7 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 31519472)
Free to read 0 / 2 Behind a paywall — scores zero
Total 71 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.

Later studies that cite this one

24 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Risk factors from nearby years

Also tagged “lewy”

1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Risk factors

See all studies in Risk factors →